SAN JOSE, Calif., Sept. 26, 2019 /PRNewswire/ -- Anpac Bio-Medical Science Co., Ltd. ("Anpac Bio"), a biotechnology company focusing on early cancer screening and detection, announced that the company's United States subsidiary, Anpac Technology USA Co., Ltd., has received a certificate of registration under the U.S.

DUBLIN, Sept. 26, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conferenc

VANCOUVER, British Columbia, Sept. 26, 2019 /PRNewswire/ -- Dreem has announced the winners of its first call for proposals at the World Sleep Congress in Vancouver. The call for proposals was designed to reward innovative research projects that use sleep endpoints. The study of sleep endpoints has traditionally been restricted to a clini

INDIANAPOLIS, Sept. 26, 2019 /PRNewswire/ -- Today at the Indiana Life Sciences Summit, BioCrossroads' Board of Directors named Dr. Clem J. McDonald recipient of the 2019 August M. Watanabe Life Sciences Champion of the Year Award. The prestigious honor named in tribute to BioCrossroads' late Chairman August Watanabe

SAN FRANCISCO, Sept. 26, 2019 /PRNewswire/ --

SAN FRANCISCO, Sept. 26, 2019 /PRNewswire/ -- VITAS Healthcare, the nation's leading provider of end-of-life care, celebrated the opening of its

AKRON, Ohio, Sept. 26, 2019 /PRNewswire/ -- Crystal Clinic Plastic Surgeons will host its third annual Pink Runway event on Tuesday, Oct. 15, 2019 from 6:30 p.m. to 8:30 p.m. at Bradley's Catering, 507 S. Cleveland-Massillon Road in Fairlawn. Doors open at

RICHMOND, Va., Sept. 26, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) announces that the National Institutes of Health (NIH) has granted Indivior's application entitled  "Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder" pursuant to Funding Opportunity Announcement RFA-D

SAN FRANCISCO and MARLBOROUGH, Mass., Sept. 26, 2019 /PRNewswire/ -- Boston Scientific (NYSE: BSX) has announced primary endpoint results from the EVOLVE Short DAPT clinical trial, the first prospective study initiated in the U.S. to examine the safety of a shortened duration of dual antiplatelet therapy (DAPT) in patients at high risk for bleeding. Res

SILVER SPRING, Md., Sept. 26, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration today expanded the approval of Mavyret (glecaprevir and pibrentasvir) tablets for an eight-week duration for the treatment of adults and children ages 12 years and older or weighing at least 99 pounds who have chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection and